The effectiveness of biotechnology policies in Europe Online publication date: Wed, 16-Jul-2008
by Christien Enzing, Thomas Reiss
International Journal of Biotechnology (IJBT), Vol. 10, No. 4, 2008
Abstract: The present study investigates what policy mixes are the most effective in fostering biotechnology innovations. An input-output approach has been used with a mix of biotechnology policy instruments at the input side and biotechnology performance in science and commercialisation at the output side. Policy mixes that include both generic and biotech-specific policy instruments which support both the science base and commercialisation activities correlate with higher performance levels. Countries that ascribe limited importance to the creation of generic and biotech-specific instruments for the stimulation of biotechnology also perform more weakly. Only generic research stimulating instruments in place is less effective; biotech-specific instruments seem to be more beneficial. All highly performing countries in commercialisation had both generic and biotech-specific instruments in place. The overall conclusion is that a well-balanced mix of generic and biotech-specific measures seems to be superior.
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Biotechnology (IJBT):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email subs@inderscience.com
Our Blog 
Follow us on Twitter 
Visit us on Facebook